Literature DB >> 20134483

The expanding role of biologic therapy for IBD.

Stephen B Hanauer.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20134483     DOI： 10.1038/nrgastro.2009.238

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

Review 1.  Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations.

Authors:  Yusuf Yazici; Tuulikki Sokka; Theodore Pincus
Journal:  Rheum Dis Clin North Am       Date:  2009-11       Impact factor: 2.670
  1 in total
  6 in total

1.  Multivariate modeling identifies neutrophil- and Th17-related factors as differential serum biomarkers of chronic murine colitis.

Authors:  Megan E McBee; Yu Zeng; Nicola Parry; Cathryn R Nagler; Steven R Tannenbaum; David B Schauer
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

2.  Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn's Disease.

Authors:  Yanmin Guo; Guangxi Zhou; Chong He; Wenjing Yang; Zhenkun He; Zhanju Liu
Journal:  Mediators Inflamm       Date:  2015-05-28       Impact factor: 4.711

3.  Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa.

Authors:  Lijuan Yu; Xuehua Yang; Lu Xia; Jie Zhong; Wensong Ge; Jianxin Wu; Hongchun Liu; Fei Liu; Zhanju Liu
Journal:  Mediators Inflamm       Date:  2015-03-19       Impact factor: 4.711

4.  Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab.

Authors:  Timothy Fitzgerald; Richard Melsheimer; Marie-Hélène Lafeuille; Patrick Lefebvre; Laura Morrison; Kimberly Woodruff; Iris Lin; Bruno Emond
Journal:  Biologics       Date:  2021-01-06

Review 5.  Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence.

Authors:  Marko Kumric; Tina Ticinovic Kurir; Dinko Martinovic; Piero Marin Zivkovic; Josko Bozic
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

6.  JNK Pathway-Associated Phosphatase/DUSP22 Suppresses CD4+ T-Cell Activation and Th1/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease.

Authors:  Rui Zhou; Ying Chang; Jing Liu; Min Chen; Hongling Wang; Meifang Huang; Shi Liu; Xiaobing Wang; Qiu Zhao
Journal:  Front Immunol       Date:  2017-07-04       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.